PATENT CLAIM ANALYSIS

Application Number: 16239051
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-08
Patent Classification: ["514", "264100"]

Abstract:
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.

Claim (Index 43):
The method of  claim 40 , wherein said cancer is selected from hepatocellular cancer, breast cancer, bladder cancer, colorectal cancer, melanoma, mesothelioma, lung cancer, prostate cancer, pancreatic cancer, testicular cancer, thyroid cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, uterine cancer, and rhabdosarcoma.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 99.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15047892', '15408001', '15047876', '15047903', '15874299']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.844248288034178
- 35 USC 102 Novelty (BERT): 0.5524338845063471
- Combined Prediction Score: 0.8150668476813949
- Mean Citation Score: 427.961696
- Max Citation Score: 462.39725
- Similarity Product: 257.5881123913676

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test